Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly for those with actionable ...

MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an update. On December 10, 2025, MAIA Biotechnology announced a significant ...

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...

Quality of life emerges as a central theme, with panelists emphasizing that patient-reported outcomes and psychosocial ...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage ...

Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity ...

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing ...

Tumor treating fields are emerging as a promising option for treating a range of cancer types. Here’s a look at the evidence ...